首页膀胱肿瘤诊断证据详情

Comparative sensitivity and specificity of imaging modalities in staging bladder cancer prior to radical cystectomy: a systematic review and meta-analysis

原文: 2019 年 发布于 Cancer Management and Research 7 卷 第 4 期 224-229 浏览量:196次

作者: Crozier J. Papa N. Perera M. Ngo B. Bolton D. Sengupta S. Lawrentschuk N.

作者单位: 中山大学肿瘤防治中心华南肿瘤学国家重点实验室肿瘤医学协同创新中心泌尿外科 中山大学肿瘤防治中心华南肿瘤学国家重点实验室肿瘤医学协同创新中心结直肠科 中山大学肿瘤防治中心华南肿瘤学国家重点实验室肿瘤医学协同创新中心重症监护室 中山大学肿瘤防治中心华南肿瘤学国家重点实验室肿瘤医学协同创新中心护理部

归属分类: 膀胱肿瘤诊断证据

DOI: 10.27020/d.cnki.gfjyu.2020.000289

关键词: Administration Intravesical Antibiotics Antineoplastic/*administration & dosage BCG Vaccine/administration & dosage Carcinoma in Situ/*drug therapy/mortality/pathology Carcinoma Transitional Cell/*drug therapy/mortality/pathology Disease Progression Electrochemotherapy/adverse effects/*methods Humans Mitomycin/*administration & dosage Neoplasm Recurrence Local Randomized Controlled Trials as Topic Time Factors Urinary Bladder Neoplasms/*drug therapy/mortality/pathology

文献简介

Pioglitazone has been reported to increase the risk of bladder cancer but the conclusions of published clinical studies are confusing. We conducted a systematic review and meta-analysis of all eligible randomized controlled trial (RCT) studies and observational studies, in order to identify a more precise relationship between pioglitazone and risk of bladder cancer. We searched for publications up to January 24, 2018, in PubMed, EMBASE, Scopus, Web of Science, Cochrane register, and Chinese National Knowledge Infrastructure databases, and the references of the retrieved articles and relevant reviews were also checked. Relative risk and 95% confidence interval (CI) were used to assess this correlation. A dose-related meta-analysis was performed as well. Data on RCT studies showed a null association between pioglitazone and bladder cancer. The pooled RR estimates of the 12 included studies illustrated that pioglitazone is associated with a 14% increased risk of bladder cancer (95% CI 1.03-1.26). No evidence of publication bias was detected. In the dose effect analysis, patients who used a higher dose of pioglitazone had an increased risk of bladder cancer. In conclusion, this meta-analysis indicated that pioglitazone is associated with an increased risk of bladder cancer. Further research should be conducted to confirm our findings and reveal the potential biological mechanisms.

热门文献